1. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort 
Rupert C M Jones, MD, Prof David Price, MD, Dermot Ryan, MD, Erika J Sims, PhD, Julie von Ziegenweidt, Laurence Mascarenhas, MSc, Anne Burden, MSc, David M G Halpin, DPhil, Robert Winter, MD, Prof Sue Hill, PhD, Matt Kearney, MRCGP, Kevin Holton, Anne Moger, MSc, Daryl Freeman, MRCGP, Alison Chisholm, MSc, Prof Eric D Bateman, PhD 
The Lancet Respiratory Medicine 
Volume 2, Issue 4, Pages (April 2014)
DOI: /S (14)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1 Study population
*Any of shortacting β2 agonist, longacting β2 agonist, inhaled corticosteroid, shortacting anticholinergic, longacting anticholinergic, leukotriene receptor antagonist, or theophylline. COPD=chronic obstructive pulmonary disease.
The Lancet Respiratory Medicine 2014 2, DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2 Mean frequency of missed opportunities to diagnose COPD
For consultations for lower respiratory symptoms (A), lower respiratory prescribing consultations (B), chest radiography (C), and outpatient consultations (D). Too few data were available to present number of admissions to hospital. COPD=chronic obstructive pulmonary disease.
The Lancet Respiratory Medicine 2014 2, DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3
Prevalence of comorbidity at the time of COPD diagnosis for patients diagnosed between 1990 and 2009
The Lancet Respiratory Medicine 2014 2, DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions